第三代EGFR-TKI奥希替尼的耐药机制探讨及处理策略  

Rerview on the resistance mechanisms of the third-generation EGFR-TKI Osimertinib and the therapeutic strategies

作　　者：袁媛[1] 谷伟[1] Yuan Yuan;Gu Wei(Department of Respiratory Medicine,Nanjing Hospital Affiliated to Nanjing Medical University,Nanjing First Hospital,Nanjing 210006,China)

机构地区：[1]南京医科大学附属南京医院、南京市第一医院呼吸科,210006

出　　处：《国际呼吸杂志》2018年第18期1414-1418,共5页International Journal of Respiration

基　　金：江苏省临床医学科技专项课题（BE201561i）

摘　　要：对于因出现T790M突变而对一代表皮生长因子受体一酪氨酸激酶抑制剂（EGFR-TKI）吉非替尼、厄洛替尼或二代TKI阿法替尼等产生耐药的非小细胞肺癌患者来说，第三代EGFR-TKI奥希替尼已经被美国食品药品管理局批准投入耐药治疗。尽管奥希替尼可延长患者生存时间，但在治疗约10个月后获得性耐药仍会出现。目前对奥希替尼耐药性已有报道，但具体机制仍不清楚。本文对奥希替尼耐药的可能机制和应对策略作一个系统性回顾。The third-generation epidermal growth factor receptor-tyrosine kinase inhibitor（EGFR- TKI） osimertinib has received approval by the Food and Drug Adiministration for the treatment of epidermal growth factor receptor T790M mutation-psoitive non-small cell lung cancer with progression following the first-generation EGFR-TKI such as gefitinib and erlotinib or the second-generation EGFR TKI like afatinib. Dspite osimertinb treatment signigicantly prolonged overall survival, emergency of acquired resistance after 10 monthes is almost inevitable. Occurance of acquired resistance to osimertinib has been reported. However, the concrete mechanisms is still unclear. The aim of the paper is to provide a comprehensive overview of the mechanisms of acquired resisitance to osimertinib and give the therapeutic strategies.

关 键 词：非小细胞肺癌 表皮生长因子受体 奥希替尼 耐药 

分 类 号：R734.2[医药卫生—肿瘤]